Additional Measures After Stopping Nucleoside Analogues in HbeAg-Negative Chronic Hepatitis B: Better But Not Enough

Gastroenterology. 2024 Jan;166(1):23-24. doi: 10.1053/j.gastro.2023.10.005. Epub 2023 Oct 12.

Authors

Seng Gee Lim¹, Yong Chuan Tan²

Affiliations

¹ Division of Gastroenterology and Hepatology, Department of Medicine, National University Health System; Yong Loo Lin School of Medicine, National University of Singapore, Singapore. Electronic address: mdclimsg@nus.edu.sg.
² Division of Gastroenterology and Hepatology, Department of Medicine, National University Health System, Singapore.

PMID: 37832923
DOI: 10.1053/j.gastro.2023.10.005

No abstract available

Publication types

Editorial

MeSH terms

Antiviral Agents / therapeutic use
DNA, Viral
Hepatitis B Surface Antigens
Hepatitis B e Antigens
Hepatitis B virus / genetics
Hepatitis B, Chronic* / diagnosis
Hepatitis B, Chronic* / drug therapy
Humans
Nucleosides / therapeutic use
Treatment Outcome

Substances

Hepatitis B e Antigens
Nucleosides
Antiviral Agents
DNA, Viral
Hepatitis B Surface Antigens